Jonathan Aschoff
Stock Analyst at Roth Capital
(0.41)
# 4,157
Out of 4,984 analysts
39
Total ratings
21.57%
Success rate
-38.71%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.83 | +1,233.33% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $7.26 | +189.26% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $1.50 | +394,566.67% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.48 | +1,116.22% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $4.13 | +17,188.14% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.70 | +2,768.21% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.37 | +10,580.91% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $5.13 | +16,274.27% | 4 | Mar 28, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $25 → $36 | $9.71 | +270.75% | 1 | Mar 7, 2024 | |
| HSDT Helius Medical Technologies | Maintains: Buy | $3,750 → $18,000 | $22.33 | +80,509.05% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $6.30 | +376.19% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $6.33 | +3,059.56% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.00 | +600.00% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $1.58 | +1,366,988.61% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.17 | +583.76% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $3.71 | +2,595.42% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.87 | +45,834.77% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $7.11 | +434.46% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360,000 | $2.88 | +12,499,900.00% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.28 | +4,110.53% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.99 | +553.27% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.83
Upside: +1,233.33%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $7.26
Upside: +189.26%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $1.50
Upside: +394,566.67%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.48
Upside: +1,116.22%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $4.13
Upside: +17,188.14%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.70
Upside: +2,768.21%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.37
Upside: +10,580.91%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $5.13
Upside: +16,274.27%
Mind Medicine (MindMed)
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $9.71
Upside: +270.75%
Helius Medical Technologies
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $22.33
Upside: +80,509.05%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $6.30
Upside: +376.19%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $6.33
Upside: +3,059.56%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.00
Upside: +600.00%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $1.58
Upside: +1,366,988.61%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.17
Upside: +583.76%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $3.71
Upside: +2,595.42%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.87
Upside: +45,834.77%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $7.11
Upside: +434.46%
Feb 12, 2021
Initiates: Buy
Price Target: $360,000
Current: $2.88
Upside: +12,499,900.00%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.28
Upside: +4,110.53%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.99
Upside: +553.27%